Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kluth

Showing results (621-630 of 1,145) with videos related to

Pageof 115
Sort By:
The Prostate|September 15, 2021
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Frontiers in Oncology|December 10, 2021
Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer PatientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Oncotarget|August 22, 2015
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancerMartina Kluth, Ramin Ahrary, Claudia Hube-Magg, et al.
Cancer Management and Research|December 5, 2018
Deletion of 3p13 is a late event linked to progression of <i>TMPRSS2</i>:<i>ERG</i> fusion prostate cancerMartina Kluth, Heinke Volta, Mohammad Hussein, et al.
Journal of Clinical Medicine|July 2, 2021
Contemporary Outcomes after Transurethral Procedures for Bladder Neck Contracture Following Endoscopic Treatment of Benign Prostatic HyperplasiaClemens M Rosenbaum, Malte W Vetterlein, Margit Fisch, et al.
Oncotarget|November 19, 2016
Deletion of 18q is a strong and independent prognostic feature in prostate cancerMartina Kluth, Maximilian Graunke, Christina Möller-Koop, et al.
Experimental and Molecular Pathology|March 22, 2015
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancerChristoph Burdelski, Oliver M Ruge, Nathaniel Melling, et al.
European Urology Open Science|March 6, 2023
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort StudyStefanie Fischer, Christian Rothermundt, Odile Stalder, et al.
Cytotherapy|March 18, 2019
In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trialsNils Tappenbeck, Hannes M Schröder, Elke Niebergall-Roth, et al.
Genes, Chromosomes & Cancer|January 10, 2019
5q21 deletion is often heterogeneous in prostate cancerMartina Kluth, Zaid Al Kilani, Cansu Özden, et al.
Pageof 115

Showing results (621-630 of 1,145) with videos related to

Sort By:
Pageof 115
The Prostate|September 15, 2021
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Frontiers in Oncology|December 10, 2021
Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer PatientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Oncotarget|August 22, 2015
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancerMartina Kluth, Ramin Ahrary, Claudia Hube-Magg, et al.
Cancer Management and Research|December 5, 2018
Deletion of 3p13 is a late event linked to progression of <i>TMPRSS2</i>:<i>ERG</i> fusion prostate cancerMartina Kluth, Heinke Volta, Mohammad Hussein, et al.
Journal of Clinical Medicine|July 2, 2021
Contemporary Outcomes after Transurethral Procedures for Bladder Neck Contracture Following Endoscopic Treatment of Benign Prostatic HyperplasiaClemens M Rosenbaum, Malte W Vetterlein, Margit Fisch, et al.
Oncotarget|November 19, 2016
Deletion of 18q is a strong and independent prognostic feature in prostate cancerMartina Kluth, Maximilian Graunke, Christina Möller-Koop, et al.
Experimental and Molecular Pathology|March 22, 2015
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancerChristoph Burdelski, Oliver M Ruge, Nathaniel Melling, et al.
European Urology Open Science|March 6, 2023
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort StudyStefanie Fischer, Christian Rothermundt, Odile Stalder, et al.
Cytotherapy|March 18, 2019
In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trialsNils Tappenbeck, Hannes M Schröder, Elke Niebergall-Roth, et al.
Genes, Chromosomes & Cancer|January 10, 2019
5q21 deletion is often heterogeneous in prostate cancerMartina Kluth, Zaid Al Kilani, Cansu Özden, et al.
Pageof 115